Frontlight ResearchEarly access
CompletedPhase 2
REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant
Key facts
- Who runs it
- Duke University
- Where
- Durham, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 142 people enrolled
- Started
- 28 Jun 2023
- Ended
- 7 Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Suvorexant 20 mg
- Placebo
- Record updated
- 15 January 2026
Who can take part
- Age
- 65 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Age 65 and older
- Undergoing non-cardiac, non-intracranial surgery, any surgical procedure not involving the skull, brain, cerebrovascular structures
- Scheduled postoperative inpatient overnight stay
- Able to give informed consent or has legally authorized representative able to give informed consent on their behalf
- English-speaking
Who cannot take part
- Use of outpatient sedating sleep aids > 2 times per any week in 1 month preceding day of surgery. Sedating sleep aids, *See list Below
- Use of systemic (oral, intravenous, intramuscular, subcutaneous) moderate or strong CYP3A inhibitors within 1 week prior to surgery, *See list below
- Use of systemic (oral, intravenous, intramuscular, subcutaneous) moderate or strong CYP3A inducers within 1 week prior to surgery, *See list below
- Undergoing surgery that will result in inability to take medications by mouth including laryngectomy, tracheostomy, and oral resection/reconstructive surgery
- Undergoing surgery that will require postoperative strict bowel rest, including gastrectomy, esophagectomy, and pancreaticoduodenectomy
- Undergoing surgery in an area that will make it unsafe to wear a headband, such as scalp or forehead procedures
- Inappropriate for study inclusion based on the judgement of the principal investigator; Exclusionary Medications:; Moderate CYP3A inhibitors: Amprenavir, Aprepitant, Atazanavir, Ciprofloxacin, Diltiazem, Erythromycin, Fluconazole, Fosamprenavir, Imatinib, Verapamil, grapefruit juice; Strong CYP3A inhibitors: Ketoconazole, Itraconazole, Posaconazole, Clarithromycin, Nefazodone, Ritonavir, Saquinavir, Nelfinavir, Indinavir, Boceprevir, Telaprevir, Telithromycin, Conivaptan; Moderate/Strong CYP3A inducers: Apalutamide, Carbamazepine, Enzalutamide, Ivosidenib, lumacaftor, Mitotane, Phenytoin, Rifampin, St. John's wort, Bosentan, Cenobamate, Dabrafenib, Efavirenz, Etravirine, Lorlatinib, Pexidartinib, Phenobarbital, Primidone, Sotorasib; Sedating sleep aids: Mirtazapine, Trazodone, Flurazepam, Temazepam, Triazolam, Estazolam, Quazepam, Clonazepam, Lorazepam, Midazolam, Alprazolam, Diazepam, Zolpidem, Zaleplon, Eszopiclone, Diphenhydramine, Doxylamine, Hydroxyzine, Suvorexant, Doxepin
- History of psychotic disorder, including schizophrenia, schizoaffective disorder, schizophreniform or brief psychotic disorder
- History of severe sleep apnea or obesity hypoventilation syndrome requiring home bilevel positive airway pressure therapy or home ventilator or other forms of noninvasive ventilation
- Chronic lung disease requiring home oxygen therapy
- History of narcolepsy
- History of liver failure with documented international normalized ratio (INR) of >1.2 or with history of hepatic encephalopathy
- Inmate of correctional facility
- Body mass index> 40
- Legal blindness
- Unable to perform study related questionnaires and assessments
- Current or planned administration of digoxin, or is currently experiencing digoxin toxicity
Where in United States
- Duke University Medical CenterDurham, United States
About the trial
What the trial wants to find out
This research study will evaluate the effectiveness of postoperative administration of a drug called suvorexant, to improve postoperative sleep and decrease the severity of delirium (serious confusion) in adults 65 years and older undergoing non-cardiac surgery.
The 2 groups in the trial
- Suvorexant ArmExisting treatment, for comparison
Treatment: Suvorexant 20 mg
- Placebo ArmPlacebo, for comparison
Treatment: Placebo
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Suvorexant to Improve Postoperative Sleep and Reduce Delirium Severity in Older Surgical Patients: A Double-blinded, Randomized, Placebo-controlled Trial
- Publications
- Record updated
- 15 January 2026